These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 27540175)

  • 21. PCSK9: a key modulator of cardiovascular health.
    Seidah NG; Awan Z; Chrétien M; Mbikay M
    Circ Res; 2014 Mar; 114(6):1022-36. PubMed ID: 24625727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.
    Kotowski IK; Pertsemlidis A; Luke A; Cooper RS; Vega GL; Cohen JC; Hobbs HH
    Am J Hum Genet; 2006 Mar; 78(3):410-22. PubMed ID: 16465619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RNAi-based functional profiling of loci from blood lipid genome-wide association studies identifies genes with cholesterol-regulatory function.
    Blattmann P; Schuberth C; Pepperkok R; Runz H
    PLoS Genet; 2013; 9(2):e1003338. PubMed ID: 23468663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
    Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
    Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention.
    Zhu YM; Anderson TJ; Sikdar K; Fung M; McQueen MJ; Lonn EM; Verma S
    Arterioscler Thromb Vasc Biol; 2015 Oct; 35(10):2254-9. PubMed ID: 26293463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic variants in PCSK9 in the Japanese population: rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population.
    Miyake Y; Kimura R; Kokubo Y; Okayama A; Tomoike H; Yamamura T; Miyata T
    Atherosclerosis; 2008 Jan; 196(1):29-36. PubMed ID: 17316651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FHL5 Controls Vascular Disease-Associated Gene Programs in Smooth Muscle Cells.
    Wong D; Auguste G; Lino Cardenas CL; Turner AW; Chen Y; Song Y; Ma L; Perry RN; Aherrahrou R; Kuppusamy M; Yang C; Mosquera JV; Dube CJ; Khan MD; Palmore M; Kalra J; Kavousi M; Peyser PA; Matic L; Hedin U; Manichaikul A; Sonkusare SK; Civelek M; Kovacic JC; Björkegren JLM; Malhotra R; Miller CL
    Circ Res; 2023 Apr; 132(9):1144-1161. PubMed ID: 37017084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematic analysis of variants related to familial hypercholesterolemia in families with premature myocardial infarction.
    Brænne I; Kleinecke M; Reiz B; Graf E; Strom T; Wieland T; Fischer M; Kessler T; Hengstenberg C; Meitinger T; Erdmann J; Schunkert H
    Eur J Hum Genet; 2016 Feb; 24(2):191-7. PubMed ID: 26036859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
    Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
    Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sortilin, encoded by the cardiovascular risk gene SORT1, and its suggested functions in cardiovascular disease.
    Kjolby M; Nielsen MS; Petersen CM
    Curr Atheroscler Rep; 2015 Apr; 17(4):496. PubMed ID: 25702058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bivariate Genome-Wide Association Scan Identifies 6 Novel Loci Associated With Lipid Levels and Coronary Artery Disease.
    Siewert KM; Voight BF
    Circ Genom Precis Med; 2018 Dec; 11(12):e002239. PubMed ID: 30525989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Network analysis of coronary artery disease risk genes elucidates disease mechanisms and druggable targets.
    Lempiäinen H; Brænne I; Michoel T; Tragante V; Vilne B; Webb TR; Kyriakou T; Eichner J; Zeng L; Willenborg C; Franzen O; Ruusalepp A; Goel A; van der Laan SW; Biegert C; Hamby S; Talukdar HA; Foroughi Asl H; ; Pasterkamp G; Watkins H; Samani NJ; Wittenberger T; Erdmann J; Schunkert H; Asselbergs FW; Björkegren JLM
    Sci Rep; 2018 Feb; 8(1):3434. PubMed ID: 29467471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Anti-PCSK9 in coronary artery disease: genetic progress, therapeutic approaches].
    Abifadel M; Ghaleb Y; Elbitar S; El Khoury P; Rabès JP; Varret M; Boileau C
    Rev Prat; 2015 Mar; 65(3):326-7. PubMed ID: 26016189
    [No Abstract]   [Full Text] [Related]  

  • 35. Dynamic Role of trans Regulation of Gene Expression in Relation to Complex Traits.
    Yao C; Joehanes R; Johnson AD; Huan T; Liu C; Freedman JE; Munson PJ; Hill DE; Vidal M; Levy D
    Am J Hum Genet; 2017 Apr; 100(4):571-580. PubMed ID: 28285768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hemostatic Genes Exhibit a High Degree of Allele-Specific Regulation in Liver.
    Olsson Lindvall M; Hansson L; Klasson S; Davila Lopez M; Jern C; Stanne TM
    Thromb Haemost; 2019 Jul; 119(7):1072-1083. PubMed ID: 31035302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease.
    Zhang Y; Xu RX; Li S; Zhu CG; Guo YL; Sun J; Li JJ
    Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):426-33. PubMed ID: 25770756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LDLR and PCSK9 Are Associated with the Presence of Antiphospholipid Antibodies and the Development of Thrombosis in aPLA Carriers.
    Ochoa E; Iriondo M; Manzano C; Fullaondo A; Villar I; Ruiz-Irastorza G; Zubiaga AM; Estonba A
    PLoS One; 2016; 11(1):e0146990. PubMed ID: 26820623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent patents on PCSK9: a new target for treating hypercholesterolemia.
    Li H; Li H; Ziegler N; Cui R; Liu J
    Recent Pat DNA Gene Seq; 2009; 3(3):201-12. PubMed ID: 19601924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.